N early 14 million Americans are cancer survivors, and the survivor population is estimated to grow by nearly one third by 2022 (1) . Improved methods for early detection, more effective treatments, and overall population aging have contributed to the increase in the number of cancer survivors. Consensus-based guidelines can provide important guidance on surveillance and management because survivors will continue to face long-term late effects of treatment, including second cancer diagnoses and cardiac events.
Childhood cancer survivors represent fewer than 1% of cancer survivors (1) , but compared with adult survivors, their risk for late effects has been well-characterized by the Childhood Cancer Survivor Study (CCSS) and other cohort studies (2) (3) (4) (5) (6) (7) (8) (9) . Increased risk for cardiac events is a leading concern, especially among survivors who were treated with cardiotoxic therapies, including anthracycline and chest radiation. At 30 to 40 years after the initial cancer diagnosis, the cumulative incidence of cardiac disease among adult childhood cancer survivors is considerably greater than that of the U.S. general population (10) , ranging between 7.2% and 12.4%, and congestive heart failure (CHF) is responsible for as many as one half of cases (11, 12) .
Routine cardiac surveillance with echocardiography (and subsequent intervention if cardiomyopathy is detected) may reduce CHF risk and is currently recommended by follow-up guidelines established by the Children's Oncology Group (13) . For example, annual echocardiography is recommended for survivors who received 300 mg/m 2 or greater of doxorubicin (or equal doses of other anthracyclines [14] ) for their original cancer treatment. However, the performance characteristics of echocardiography to detect asymptomatic left ventricular dysfunction (ALVD) in this patient population is limited (15) and clinical studies on the effectiveness of angiotensin-converting enzyme (ACE) inhibitors and ␤-blockers (BBs) to reduce systolic CHF risk among pediatric cancer survivors have been inconclusive (14, 16) .
Consensus-based guidelines on cardiac assessment can provide guidance for childhood cancer survivors, but their effect on long-term outcomes is unclear. By synthesizing the best available data on CHF natural history among childhood cancer survivors, we sought to estimate the clinical benefits and cost-effectiveness of routine cardiac assessment to detect ALVD and of ACE inhibitor and BB treatment to reduce systolic CHF incidence and improve overall survival.
METHODS

Overview
We developed a state-transition model of the clinical course of systolic CHF in a cohort of patients similar to those in the CCSS (17, 18) . We estimated the lifetime risk for systolic CHF, delay in average age at CHF onset, and number of per-person echocardiography screenings associated with interval-based cardiac assessment strategies by using the model. The model projected quality-adjusted life expectancy, lifetime costs, and incremental costeffectiveness ratios (ICERs) to assess the comparative performance of the assessment strategies. We adopted a societal perspective and discounted all future costs and clinical consequences at 3% annually (19) . Costs are expressed in 2012 dollars. We assumed that interventions with ICERs less than $100 000 per QALY gained provide good value for resources invested and are therefore considered costeffective for the cost-effectiveness analysis (20) . We also conducted subgroup analyses on the basis of the total anthracycline dose received during original cancer treatment (11) . Sensitivity analyses to assess how key variables and assumptions may influence results included a probabilistic sensitivity analysis to account for uncertainty. The model was constructed using TreeAge Pro 2009 (TreeAge Software, Williamstown, Massachusetts).
CHF Simulation Model
A cohort of 5-year childhood cancer survivors aged 15 years (cancer diagnosed at age 10 years) entered the state-transition model and faced a monthly risk for ALVD (defined as left ventricular ejection fraction Ͻ50%) at the start of the simulation (Figure 1) . Persons with ALVD may develop symptomatic systolic CHF and face diseasespecific death risks. Each month, all persons faced the risk for dying of late effects (late recurrence of original cancer and noncardiac late effects, including second cancer diagnoses) and other causes.
We simulated systolic CHF risk among childhood cancer survivors using data on baseline general population risk (based on the Framingham Heart Study [21] ) and absolute excess risk (AER) (estimated from the CCSS [11] ). We assumed that all CCSS AER for CHF was due to systolic left ventricular dysfunction and, because follow-up data for the CCSS are limited, the AER for CHF increased to and then remained at rates observed between 25 and 30 years since diagnosis for the remainder of each survivor's life. On the basis of epidemiologic studies, we assumed that ALVD progressed at a constant rate to CHF after a median interval of 5.9 years (22) . Once CHF developed, persons received guideline-based care. We conducted analyses for subgroups on the basis of the total anthracycline dose received during the original cancer treatment (none, Ͻ250 mg/m 2 , and Ն250 mg/m 2 ) using data from the CCSS (Table 1) (7, 11, 15, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) .
Context
Guidelines recommend that childhood cancer survivors have periodic, lifetime echocardiography screening to detect asymptomatic left ventricular dysfunction.
Contribution
The authors used a mathematical model to compare risks for systolic congestive heart failure, quality-adjusted lifeyears, and total costs for different screening intervals applied to a hypothetical population of 5-year childhood cancer survivors who were originally diagnosed at age 10 years.
Caution
Many model variables were based on data from adults with congestive heart failure but without a history of cancer.
Implication
Although frequent, periodic echocardiography may reduce incidence of congestive heart failure, less frequent screening than what is currently recommended may be more cost-effective. 
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Health states for the CHF model are depicted. Persons enter the model with no ALVD and face monthly rates of developing ALVD on the basis of age-specific CHF rates. Persons with ALVD face the risk for symptomatic CHF. Once CHF develops, persons face disease-specific death risks. All persons face death risks from background mortality, late recurrence, and noncardiac late effects (including second cancer diagnoses and pulmonary, external, and other causes). Persons are followed throughout their lifetime. ALVD ϭ asymptomatic left ventricular dysfunction; CHF ϭ congestive heart failure. ACE ϭ angiotensin-converting enzyme; AER ϭ absolute excess risk; ALVD ϭ asymptomatic left ventricular dysfunction; APC ϭ ambulatory payment classification; BB ϭ ␤-blocker; CHF ϭ congestive heart failure; CPT ϭ Current Procedural Terminology; DRG ϭ diagnosis-related group; NYHA ϭ New York Heart Association; RR ϭ relative risk; YSD ϭ years since diagnosis. * The underlying CHF risk was proportionally adjusted to account for competing risks so that model outcomes matched observed estimates of age-specific CHF risk (11, 21) . † Assumed that 46% of all CHF was systolic-related (34) . ‡ Value of multiplicative factor variable applied to the base-case value in sensitivity analysis. § Assumed an annual rate equal to the average of 0-to 24-y and 35-to 44-y rates because of limited CHF data on adults aged Ͻ35 y. Range based on subgroup-specific AER for CHF estimated for each anthracycline subgroup using data from the Childhood Cancer Survivor Study from Mulrooney et al (11) on overall CHF risk, RR for CHF associated with each anthracycline dose, and prevalence of each anthracycline dose subgroup. ¶ Truncated to values Ն1.0 (RRs for CHF for anthracycline subgroups), Ն0 (late-recurrence and noncardiac late-effects mortality rates), or Յ1.0 (heart failure treatment RR benefit and utility weights). ** Constant rate, based on the assumption that median time to onset of CHF is 5.9 y. Median time was varied from 3.4 to 10.4 y in sensitivity analysis. † † Distributions previously described (7, 26) . ‡ ‡ Assumed that all persons with symptomatic CHF received ACE inhibitor and BB treatment as part of guideline-based care (35) . § § Assumed that utility weights were multiplicative. Range for sensitivity analysis was Ϯ25% of base-case estimate, except for drug costs, which are based on wholesale acquisition cost range among leading manufacturers. We assumed that costs were fixed and did not vary them in probabilistic sensitivity analysis. ¶ ¶ Assumed that all echocardiography was done in an outpatient facility. *** Assumed that 28% of persons with symptomatic CHF require hospitalization (36) .
Strategies
Compared with no cardiac assessment, we evaluated routine assessment with 2-dimensional (2D) biplane echocardiography every 1, 2, 5, or 10 years. Test characteristics of echocardiography to detect ALVD were based on a study of adult survivors of childhood cancer that compared 2D echocardiography with cardiac magnetic resonance imaging (cMRI) (the reference standard for comparing measurement of cardiac structure and function) (15) . We assumed that all persons whose echocardiograms showed reduced left ventricular function received ALVD treatment.
Other Clinical Data Table 1 shows select model variables and their plausible ranges. We based treatment effectiveness on the SOLVD (Studies of Left Ventricular Dysfunction) prevention trial post hoc analysis (28) because data on ACE inhibitors and BBs effectiveness among childhood cancer survivors have been inconclusive (16, (37) (38) (39) (40) (41) . We assumed that, among persons with ALVD, ACE inhibitors and BBs reduced the risks for systolic CHF (relative risk [RR], 0.64) and death from cardiac causes (RR, 0.67). We also assumed negligible mortality risks associated with echocardiography or ACE inhibitor and BB treatment. We incorporated age-specific (29) and disease-specific weights (30) to estimate quality-adjusted life-years (QALYs).
Cost Data
We used 2012 U.S. average Medicare reimbursement rates (31) as a proxy for direct medical costs associated with routine cardiac assessment, follow-up care for reduced leftventricular function on echocardiograms, and ALVD and CHF treatment ( Table 1) . Persons whose echocardiograms showed reduced left ventricular function received guidelinebased care for ALVD (ACE inhibitor [20 mg of lisinopril per day] and BB [25 mg of carvedilol twice per day] treatment, physician visit every 6 months, and annual echocardiography) (35) . All persons received guideline-based care for CHF (that is, ACE inhibitor [20 mg of lisinopril per day] and BB [25 mg of carvedilol twice per day] treatment, physician visit every 3 months, and annual echocardiography) after developing symptomatic CHF. We assumed that abnormal echocardiography results did not lead to any additional diagnostic tests or procedures that would incur additional costs (nor detect other types of cardiac abnormalities). Drug costs were based on mean wholesale acquisition cost among manufacturers (32) . Indirect patient costs were based on time lost from work and the 2011 median hourly wage (33).
Sensitivity Analysis
We conducted sensitivity analyses on key model variables, including ACE inhibitor and BB treatment effectiveness, echocardiography test performance, AER for CHF, and screening and treatment costs, as well as probabilistic sensitivity analysis, to evaluate variable uncertainty ( Table 1) .
Role of the Funding Source
The National Cancer Institute funded this research. The funding source had no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
RESULTS
Reduction in Systolic CHF Incidence
At 30 to 35 years since diagnosis, the model estimated a cumulative systolic CHF incidence of 3.6% to 5.0%, which approximated published CCSS estimates (4.1%), for the overall cohort of 5-year childhood cancer survivors aged 15 years (11). The expected lifetime risk for systolic CHF was 18.8% ( Table 2) . Compared with the general population (which faced 0 risk for AER for CHF or lateeffects mortality rates and had a lifetime risk for systolic CHF of 9.4%), childhood cancer survivors had a 2.0-fold greater lifetime risk for CHF (Figure 2 ). The lifetime risk for ALVD was 22.6% and the lifetime risk for dying of CHF was 11.1% for the modeled cohort.
Routine cardiac assessment every 10 years with 2-dimensional echocardiography (beginning 5 years after diagnosis and repeated at 10-year intervals) reduced lifetime risk for systolic CHF by 2.3%, and more frequent assessment further reduced this risk ( Table 2 ). The average age at CHF onset was 58.8 years (compared with 75.5 years for the general population) with no screening. Routine assessment every 10 years delayed the average age at onset by 0.2 years and annual assessment by 0.9 years ( Table 2) .
The lifetime risk for systolic CHF was 12.6% for the subgroup that did not receive anthracycline, 19.8% for the low-risk anthracycline subgroup (Ͻ250 mg/m 2 ), and 31.8% for the high-risk anthracycline subgroup (Ն250 mg/m 2 ) (Figure 2) . The average age at CHF onset differed by subgroup with no screening, and the delay in average age at onset for each assessment schedule was greater for the high-risk subgroup (Ն250 mg/m 2 of anthracycline) ( Table 2) .
Number of Echocardiography Screenings
The average lifetime per-person number of echocardiography screenings before CHF diagnosis (including evaluations for routine screening and guideline-based ALVD care) varied by assessment strategy. There were 8.2 (range, 5.5 to 15.5) screenings for assessment every 10 years. There were 14.7 (range, 10.4 to 24.6), 30.2 (range, 24.0 to 39.4), and 48.0 (range, 45.6 to 49.7) echocardiography screenings for assessment every 5 years, 2 years, or 1 year, respectively. Results were similar among subgroups.
Cost-Effectiveness of Routine Cardiac Assessment
Cardiac assessment of childhood cancer survivors every 10 years had an ICER of $111 600 per QALY gained ( Table 2 ) compared with no assessment. Compared with Original Research Routine Echocardiography Screening for ALVD in Childhood Cancer Survivors assessment every 10 years, assessment every 5 years had an ICER of $117 900 per QALY gained. Incremental costeffectiveness ratios for more frequent assessment exceeded $165 000 per QALY gained. Incremental cost-effectiveness ratios were more favorable for female patients and persons diagnosed with cancer at ages younger than 5 years (mean age, 2 years) (Appendix Table 1 , available at www .annals.org).
Incremental cost-effectiveness ratios for all assessment strategies exceeded $196 000 per QALY gained for the subgroup that received no anthracycline (results not shown). At a cost-effectiveness threshold of $100 000 per QALY gained, assessment every 2 years was the preferred strategy for the high-risk subgroup (Ն250 mg/m 2 of anthracycline) and no assessment for the low-risk subgroup (Ͻ250 mg/m 2 of anthracycline). The ICER for assessment every 1 year was unattractive for both anthracycline subgroups (Ͼ$139 000 per QALY gained).
Sensitivity Analysis
Results were most sensitive to ACE inhibitor and BB treatment effectiveness, AER of CHF among childhood cancer survivors, and ALVD asymptomatic period ( Figure  3) . Results were moderately sensitive to echocardiography test characteristics and costs. Results were insensitive to CHF death risk, CHF treatment costs, and disutility associated with adverse events caused by ACE inhibitor and BB treatment. For example, if ALVD remained asymptomatic for a longer period (10.4 years vs. 5.9 years in the base case), ICERs for assessment every 10 and 5 years decreased from greater than $100 000 per QALY gained to less than $80 000 per QALY gained. In contrast, if all persons with CHF required hospitalization that cost 10-fold more than base-case estimates, the ICER for assessment every 10 years only decreased to $103 500 per QALY gained.
We identified threshold values of relative risk for specific strategies to understand how the optimal frequency of 2D echocardiography assessment depended on the assumption of treatment effectiveness (Figure 4, panel A) . Given a cost-effectiveness threshold of $100 000 per QALY gained, the relative reduction in CHF risk required for assessment every 1 year to be the preferred strategy fell within the 95% CI of the SOLVD prevention trial (RR, 0.49 to 0.83) (28) for only the high-risk subgroup (RR, 0.53).
Given the low sensitivity of 2D echocardiography, we explored how ICERs varied if cMRI, with perfect sensitivity and specificity for ALVD, was used instead. At a cost of echocardiography strategies (was more effective and either less costly or more cost-effective). At a $100 000-per-QALY gained threshold, cMRI assessment every 10 years was preferred for the overall cohort and low-risk subgroup and assessment every 5 years for the high-risk subgroup (Appendix Table 2 , available at www.annals.org). In addition, if ACE inhibitor and BB treatment could completely reduce CHF risk (RR, 0), assessment every 1 year would still not be the preferred strategy for any subgroup (Figure 4 panel B) . See the Appendix Figure ( available at www.annals.org) for additional sensitivity analyses. Based on probabilistic sensitivity analysis, the probability that assessment every 10 or 5 years was the preferred strategy at a cost-effectiveness threshold of $100 000 per QALY gained was 0.33 for the overall cohort and 0.34 for the low-risk anthracycline subgroup. The probability that assessment every 2 years was preferred was 0.57 for the high-risk anthracycline subgroup. Figure 5 and Table 2 provide additional details.
DISCUSSION
Although 5-year survival rates have increased over the past several decades, childhood cancer survivors continue to face complex health challenges as they enter adulthood. Follow-up guidelines may help survivors navigate their health needs and help physicians determine optimal screening strategies. By incorporating the best available data on CHF risk and other late-effects mortality rates, our modelbased approach suggests that follow-up routine cardiac assessment may improve overall survival and reduce systolic CHF risk in as many as 1 in every 12 survivors. However, less frequent assessment than the schedule currently recommended by the Children's Oncology Group guidelines (13) ( Table 3 ) may be more reasonable for preventing CHF among childhood cancer survivors.
Whereas previous studies have focused on ALVD screening for the general population (42), our study focuses on identifying the optimal interval of assessment among childhood cancer survivors and understanding the underlying tradeoffs among clinically relevant strategies. For example, our model estimates that the lifetime perperson number of echocardiography screenings varied by 6-fold between assessments every 1 and 10 years, suggesting that, in addition to societal costs, the patient burden associated with recommended guidelines may be an important factor for survivors and their providers to consider in designing a survivorship care plan.
Our findings are based on 2 major assumptions: All CHF reported in the CCSS cohort is related to systolic left ventricular dysfunction, and ACE inhibitor and BB treatment effectively reduces CHF risk among childhood cancer survivors. As such, our estimates should be considered very optimistic. In particular, our findings assume that the effectiveness of ACE inhibitor and BB treatment to prevent progression of ALVD to CHF seen in older adults is generalizable to childhood cancer survivors despite evidence from clinical studies that question this assumption (37) (38) (39) (40) (41) . In addition, childhood cancer survivors (particularly those treated with cardiac radiation) can present with a CHF ϭ congestive heart failure. A. Cumulative systolic CHF incidence by years since diagnosis for the cohort of childhood cancer survivors (overall and anthracycline subgroups) and general population is shown. Compared with that of the general population, the lifetime relative risk for CHF is 1.3 (range, 1.1 to 1.7) for no anthracycline, 2.1 (range, 1.2 to 3.1) for Ͻ250 mg/m 2 of anthracycline, and 3.4 (range, 2.2 to 4.4) for Ն250 mg/m 2 of anthracycline. B. The reduction in lifetime risk for systolic CHF for the assessment strategies (vs. no assessment) for the overall cohort is shown. The solid line represents the reduction using base-case estimates, and the top and bottom edges of the shaded bars depict the 95% credible interval from probabilistic sensitivity analysis based on 1000 second-order Monte Carlo simulations.
Original Research Routine Echocardiography Screening for ALVD in Childhood Cancer Survivors restrictive phenotype (43) for which ACE inhibitor treatment is not effective in reducing the risk for progression to CHF. Hence, although routine cardiac assessment may be a reasonable strategy for monitoring survivors' health, screening at currently recommended intervals is likely unnecessary for most survivors and revision of guidelines is warranted. Assessment every 2 years would be suggested for high-risk survivors treated with anthracycline (Ն250 mg/ m 2 ). No screening or infrequent screening may be preferred for low-risk persons (treated with Ͻ250 mg/m 2 of anthracycline) ( Table 3) .
Our findings provide several additional important insights. First, given the low sensitivity of echocardiography, better methods to detect ALVD are needed. However, even with cMRI, less frequent screening than currently recommended may be reasonable because our model suggests that assessment every 1 or 2 years would still not be cost-effective for all anthracycline subgroups (Appendix Table 2 ). Second, the initiation of ACE inhibitor and BB treatment before ALVD develops may improve long-term outcomes. We found that more than one third of the benefit of ACE inhibitor and BB treatment associated with routine assessment stemmed from persons who received treatment after false-positive results. In fact, our model estimates that if all survivors treated with anthracycline at a dose of 250 mg/m 2 or greater received ACE inhibitor and Relative influence of select model variables on results for the overall cohort based on 1-way sensitivity analysis. The x-axis shows the effect of changes in selected variables on the ICER of the assessment every 10 y (compared with no assessment). The y-axis shows the selected model variables, with upper and lower bounds used in the sensitivity analysis in parentheses. The shaded bars indicate the ICER variation caused by changes in the value of the indicated variable, whereas all other variables were held constant. ACE ϭ angiotensin-converting enzyme; AER ϭ absolute excess risk; ALVD ϭ asymptomatic left ventricular dysfunction; BB ϭ ␤-blocker; CHF ϭ congestive heart failure; ICER ϭ incremental cost-effectiveness ratio; QALY ϭ quality-adjusted life-year; RR ϭ relative risk. * The first number in the range indicates value yielding the lowest ICER; the second indicates value yielding the highest ICER. † ICER varied from $111 330 to $111 810/QALY gained. ‡ ICER varied from $111 520 to $111 640/QALY gained.
Original Research
Routine Echocardiography Screening for ALVD in Childhood Cancer Survivors www.annals.orgBB treatment at 5 years after the original cancer diagnosis (in lieu of routine assessment), the reduction in lifetime risk for CHF would be greater (8.9%) than the reduction attributable to screening (5.9%) but at a more favorable ICER ($18 500 per QALY for "treat all" vs. $83 600 per QALY for assessment every 2 years). However, empirical ACE inhibitor and BB treatment at 5 years has not been studied clinically and relies on extrapolation from adult studies, so these model results should be viewed as hypothesis-generating. Limitations of our study include basing AER for CHF on published estimates for the overall CCSS cohort and assuming that the AER for CHF increased to and remained at rates observed between 25 and 30 years since diagnosis. If we assumed that rates increased by 50% beyond 30 years since diagnosis, nearly 24% of all survivors would develop systolic CHF in their lifetime and assessment every 5 years would be attractive for the overall cohort (ICER, $85 700 per QALY gained). We derived subgroup-specific estimates using hazard ratios that controlled for sex, age at diagnosis, treatment era, and cardiac radiation dose (11) , but other risk factors and interactions between risk factors may influence CHF risk. In particular, we could not incorporate the added effects of radiation in our model to anthracycline subgroups because published data that could inform the magnitude were not available. Although further analysis of the effects of radiation dose on ALVD will be needed, our model suggests that cardiac radiation would have to increase the relative AER for CHF by more than 75% for routine assessment every 2 years to be cost-effective for the low-dose anthracycline subgroup, an increase that has not been seen. For example, among Dutch cancer survivors, the cumulative CHF incidence at 30 years after diagnosis was not significantly different Optimal strategy based on treatment effectiveness in a cost-effectiveness framework for 2 scenarios: when only 2D echo is available (panel A) and when 2D echo and cMRI are available (panel B). On the x-axis, the RR for CHF associated with treatment is depicted, with 0 indicating complete reduction of risk and 1.0 indicating no treatment effect. The colored regions indicate the range of values over which the specific strategy would be considered optimum given a willingness-to-pay level of $100 000/QALY gained. Black solid and dotted lines indicate the base-case estimate (RR, 0.63 [95% CI, 0.49 -0.83]) from the post hoc analysis of the SOLVD prevention trial (28) . For example, if only 2D echo is available, annual assessment was the preferred strategy only if treatment reduced CHF risk by 45% (RR, 0.55) for the high-risk subgroup receiving Ն250 mg/m 2 of anthracycline; no screening or less frequent screening was preferred at all other values. In contrast, if cMRI is also available, even if treatment completely reduced CHF risk, annual assessment was still not preferred. The 95% CI from the SOLVD prevention trial is shown to depict the uncertainty in treatment effectiveness among adults. The uncertainty range among childhood cancer survivors is likely wider, including lower and negligible benefit (37) (38) (39) (40) (41) . 2D echo ϭ 2-dimensional echocardiography; ACE ϭ angiotensin-converting enzyme; BB ϭ ␤-blocker; CHF ϭ congestive heart failure; cMRI ϭ cardiac magnetic resonance imaging; QALY ϭ quality-adjusted life-year; RR ϭ relative risk; SOLVD ϭ Studies of Left Ventricular Dysfunction.
Original Research Routine Echocardiography Screening for ALVD in Childhood Cancer Survivors among persons treated with anthracycline alone (7.5% [95% CI, 3.6% to 11.2%]) and those treated with both anthracycline and radiotherapy (7.9% [CI, 1.4% to 14.0%]) (12) . Model-based estimates of age-specific ALVD prevalence for the overall cohort were also consistent with published estimates for the general population (data not shown) (22, 44) . However, sex-specific models did not reflect the greater prevalence of ALVD seen among male compared with female patients, most likely because we did not incorporate other risk factors that influence ALVD and CHF risk and, consequently, ICERs for screening.
We assumed that the sensitivity of echocardiography remained constant even though it may increase as left ventricular ejection fraction declines. Although ICERs for assessment every 10 and 5 years were more favorable with greater sensitivity (80%) for the overall cohort (ICERs Ͻ$86 000 per QALY), more frequent assessment was still associated with high ICERs (Ͼ$210 000 per QALY), and the optimal strategy remained unchanged for the high-risk subgroup at a $100 000-per-QALY threshold.
In addition, our model did not include refractory heart failure, which is associated with poorer prognosis and Cost-effectiveness acceptability curves, which illustrate the uncertainty surrounding the estimate of ICERs, are depicted for the overall cohort (panel A), the low-risk subgroup receiving Ͻ250 mg/m 2 of anthracycline (panel B), and the high-risk subgroup receiving Ն250 mg/m 2 of anthracycline (panel C). In each panel, the probability that a given strategy is the preferred strategy is depicted across a range of cost-effectiveness thresholds. For example, at a threshold of $100 000/QALY gained, the probability that assessment every 5 y is the preferred strategy is 0.26 for the overall cohort. In contrast, the probability that assessment every 2 y was preferred was 0.57 for the high-risk anthracycline subgroup. Results are based on 1000 second-order Monte Carlo simulations in which model variables were simultaneously varied. The red dashed line indicates the $100 000/QALY threshold commonly used as a benchmark in the United States. QALY ϭ quality-adjusted life-year.
Routine Echocardiography Screening for ALVD in Childhood Cancer Survivors www.annals.orgheart transplantation (41) . Although this exclusion may underestimate the cost-effectiveness of screening, ICERs were largely insensitive to CHF treatment costs. Our findings do not account for the costs or benefits associated with the annual physical examinations currently recommended by follow-up guidelines or the effect of clinically indicated echocardiography associated with these visits. We also did not incorporate other clinical benefits from routine cardiac assessment or costs associated with additional diagnostic tests. However, we assumed that, in addition to reducing the risk for ALVD progressing to CHF, ACE inhibitor and BB treatment also reduced mortality rates from other cardiac causes, accounting for some benefit for other cardiac risk types through ALVD management (45) . Likewise, by assuming that ACE inhibitor and BB treatment reduced cardiac death risk among persons with ALVD and CHF, we potentially overestimated treatment benefit, although the effect was small (ICERs varied by approximately 5%).
Consensus-based guidelines can help childhood cancer survivors manage their late-effects risks. Model-based analyses can provide a useful framework to inform policy and practice because randomized, controlled trials to evaluate these guidelines are unlikely to be conducted. Our findings suggest that current recommendations for cardiac assessment may reduce systolic CHF incidence, but less frequent screening than currently recommended may be preferred and possible revision of current recommendations is warranted. 2D echo ϭ 2-dimensional echocardiography; cMRI ϭ cardiac magnetic resonance imaging; CHF ϭ congestive heart failure; COG ϭ Children's Oncology Group; QALY ϭ quality-adjusted life-year. * Defined as the strategy with the highest incremental cost-effectiveness ratio among strategies with incremental cost-effectiveness ratios Ͻ$100 000/QALY. Model-based results are based on the benefits associated with systolic CHF risk reduction only; routine assessment for persons who received chest radiation may benefit from detection of other cardiac conditions, such as valvular disease, not included in our estimates but reflected in the COG guidelines. † Recommended assessment frequency with echocardiography (for persons aged Ն5 y at treatment) depends on total anthracycline dose (Ͻ200 mg/m 2 , 200 to Ͻ300 mg/m 2 , or Ն300 mg/m 2 ) and chest radiation (yes or no) (13) .
Original Research Routine Echocardiography Screening for ALVD in Childhood Cancer Survivors CHF ϭ congestive heart failure; ICER ϭ incremental cost-effectiveness ratio; QALY ϭ quality-adjusted life-year.
* Subgroup-specific absolute excess risk for CHF was estimated using data from the Childhood Cancer Survivor Study from Mulrooney et al (11) .0] for ages 5-9 y compared with ages 10 -20 y at original cancer diagnosis) and prevalence of risk factors. Sex-specific baseline CHF rates (general population), CHF mortality rates, and age-specific utilities were also incorporated for sex subgroups. † Range based on 95% credible interval among 1000 second-order Monte Carlo simulations. ‡ Incremental reduction in lifetime risk for systolic CHF, delay in average age at systolic CHF onset, and ICERs may differ from those suggested by illustrated lifetime risk for systolic CHF risk, lifetime costs, and QALYs due to rounding. § Defined as the additional cost of a specific strategy divided by its additional clinical benefit, compared with the next-least-expensive strategy. Values are rounded to the nearest $100.
Based on 1000 second-order Monte Carlo simulations. Probabilities may sum to less than or greater than 1.0 due to rounding. ¶ Eliminated by extended dominance (i.e., less effective and less cost-effective than a more expensive strategy). (28) . The 95% CI from the SOLVD prevention trial is shown to depict the uncertainty in treatment effectiveness among adults. The uncertainty range among childhood cancer survivors is likely wider, including lower and negligible benefit (37) (38) (39) (40) (41) . 2D echo ϭ 2-dimensional echocardiography; ACE ϭ angiotensin-converting enzyme; BB ϭ ␤-blocker; CHF ϭ congestive heart failure; cMRI ϭ cardiac magnetic resonance imaging; RR ϭ relative risk; QALY ϭ quality-adjusted life-year; SOLVD ϭ Studies of Left Ventricular Dysfunction.
